Dynavax Technologies Long Term Debt 2010-2022 | DVAX

Dynavax Technologies long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Dynavax Technologies Annual Long Term Debt
(Millions of US $)
2021 $220
2020 $180
2019 $179
2018 $101
2017 $
2016 $
2015 $
2014 $10
2013 $
2012 $
2011 $
2010 $
2009 $
Dynavax Technologies Quarterly Long Term Debt
(Millions of US $)
2022-03-31 $221
2021-12-31 $220
2021-09-30 $220
2021-06-30 $220
2021-03-31 $180
2020-12-31 $180
2020-09-30 $180
2020-06-30 $180
2020-03-31 $180
2019-12-31 $179
2019-09-30 $178
2019-06-30 $177
2019-03-31 $176
2018-12-31 $101
2018-09-30 $100
2018-06-30 $100
2018-03-31 $99
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30 $8
2015-03-31 $9
2014-12-31 $10
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30 $15
2009-06-30 $15
2009-03-31 $15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.637B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00